{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:28:27Z","timestamp":1785767307504,"version":"3.56.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"DOI":"10.1007\/s11906-026-01364-9","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:18:04Z","timestamp":1773659884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Opportunities Targeting the ACE2\/Ang-(1\u20137)\/MasR Pathway in Cardiometabolic Disease"],"prefix":"10.1007","volume":"28","author":[{"given":"Thilina U.","family":"Jayawardena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dineth P.","family":"Nagahawatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria B.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"5","key":"1364_CR1","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.cell.2023.01.039","volume":"186","author":"GY Oudit","year":"2023","unstructured":"Oudit GY, Wang K, Viveiros A, Kellner MJ, Penninger JM. Angiotensin-converting enzyme 2-at the heart of the COVID-19 pandemic. Cell. 2023;186(5):906\u201322. https:\/\/doi.org\/10.1016\/j.cell.2023.01.039.","journal-title":"Cell"},{"key":"1364_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.625732","volume":"12","author":"IO Osman","year":"2021","unstructured":"Osman IO, Melenotte C, Brouqui P, Million M, Lagier JC, Parola P, et al. Expression of ACE2, soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1\u20137) is modulated in COVID-19 patients. Front Immunol. 2021;12:625732. https:\/\/doi.org\/10.3389\/fimmu.2021.625732.","journal-title":"Front Immunol"},{"issue":"2","key":"1364_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1161\/CIRCHEARTFAILURE.113.000672","volume":"7","author":"J Mori","year":"2014","unstructured":"Mori J, Patel VB, Abo Alrob O, Basu R, Altamimi T, Desaulniers J, et al. Angiotensin 1\u20137 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db\/db mice by reducing lipotoxicity and inflammation. Circ Heart Fail. 2014;7(2):327\u201339. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.113.000672.","journal-title":"Circ Heart Fail"},{"issue":"8","key":"1364_CR4","doi-asserted-by":"publisher","first-page":"F812","DOI":"10.1152\/ajprenal.00655.2013","volume":"306","author":"J Mori","year":"2014","unstructured":"Mori J, Patel VB, Ramprasath T, Alrob OA, DesAulniers J, Scholey JW, et al. Angiotensin 1\u20137 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Ren Physiol. 2014;306(8):F812\u201321. https:\/\/doi.org\/10.1152\/ajprenal.00655.2013.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"2","key":"1364_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/FJC.0b013e3180986219","volume":"50","author":"MK Raizada","year":"2007","unstructured":"Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol. 2007;50(2):112\u20139. https:\/\/doi.org\/10.1097\/FJC.0b013e3180986219.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"1364_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIRCRESAHA.122.322003","volume":"132","author":"R Prasad","year":"2023","unstructured":"Prasad R, Floyd JL, Dupont M, Harbour A, Adu-Agyeiwaah Y, Asare-Bediako B, et al. Maintenance of enteral ACE2 prevents diabetic retinopathy in type 1 diabetes. Circ Res. 2023;132(1):e1\u201321. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.322003.","journal-title":"Circ Res"},{"issue":"1","key":"1364_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/mt.2011.155","volume":"20","author":"A Verma","year":"2012","unstructured":"Verma A, Shan Z, Lei B, Yuan L, Liu X, Nakagawa T, et al. ACE2 and Ang-(1\u20137) confer protection against development of diabetic retinopathy. Mol Ther. 2012;20(1):28\u201336. https:\/\/doi.org\/10.1038\/mt.2011.155.","journal-title":"Mol Ther"},{"key":"1364_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00201","volume":"4","author":"MC Chappell","year":"2014","unstructured":"Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the Angiotensin converting enzyme 2-Angiotensin (1\u20137)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol (Lausanne). 2014;4:201. https:\/\/doi.org\/10.3389\/fendo.2013.00201.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1364_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/HYPERTENSIONAHA.124.22693","volume":"82","author":"AC Montezano","year":"2025","unstructured":"Montezano AC, Kuriakose J, Hood KY, Sin YY, Camargo LL, Namkung Y, et al. Ang-(1\u20137) and ET-1 interplay through Mas and ET(B) receptor interaction defines a novel vasoprotective mechanism. Hypertension. 2025;82(2):267\u201381. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.22693.","journal-title":"Hypertension"},{"issue":"2","key":"1364_CR10","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1007\/s13311-020-00986-4","volume":"18","author":"R Rivas-Santisteban","year":"2021","unstructured":"Rivas-Santisteban R, Lillo J, Munoz A, Rodriguez-Perez AI, Labandeira-Garcia JL, Navarro G, et al. Novel interactions involving the Mas receptor show potential of the renin-angiotensin system in the regulation of microglia activation: altered expression in Parkinsonism and dyskinesia. Neurotherapeutics. 2021;18(2):998\u20131016. https:\/\/doi.org\/10.1007\/s13311-020-00986-4.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"1364_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1042\/CS20200480","volume":"135","author":"J Kuriakose","year":"2021","unstructured":"Kuriakose J, Montezano AC, Touyz RM. ACE2\/Ang-(1\u20137)\/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease. Clin Sci (Lond). 2021;135(2):387\u2013407. https:\/\/doi.org\/10.1042\/CS20200480.","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"1364_CR12","doi-asserted-by":"publisher","first-page":"769","DOI":"10.31083\/j.rcm2203083","volume":"22","author":"S Zhao","year":"2021","unstructured":"Zhao S, Sun W, Jiang P. Role of the ACE2\/Ang-(1\u20137)\/Mas axis in glucose metabolism. Rev Cardiovasc Med. 2021;22(3):769\u201377. https:\/\/doi.org\/10.31083\/j.rcm2203083.","journal-title":"Rev Cardiovasc Med"},{"issue":"14","key":"1364_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145131","volume":"21","author":"AJ Miller","year":"2020","unstructured":"Miller AJ, Bingaman SS, Mehay D, Medina D, Arnold AC. Angiotensin-(1\u20137) improves integrated cardiometabolic function in aged mice. Int J Mol Sci. 2020;21(14):5131. https:\/\/doi.org\/10.3390\/ijms21145131.","journal-title":"Int J Mol Sci"},{"key":"1364_CR14","doi-asserted-by":"publisher","unstructured":"Self WH, Shotwell MS, Gibbs KW, de Wit M, Files DC, Harkins M, et al. Renin-Angiotensin system modulation with synthetic angiotensin (1\u20137) and angiotensin II type 1 Receptor\u2013Biased ligand in adults with COVID-19: two randomized clinical trials. JAMA. 2023;329(14):1170\u201382. https:\/\/doi.org\/10.1001\/jama.2023.3546%J.","DOI":"10.1001\/jama.2023.3546%J."},{"issue":"2","key":"1364_CR15","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa007","volume":"4","author":"O Echeverria-Rodriguez","year":"2020","unstructured":"Echeverria-Rodriguez O, Gallardo-Ortiz IA, Del Valle-Mondragon L, Villalobos-Molina R. Angiotensin-(1\u20137) participates in enhanced skeletal muscle insulin sensitivity after a bout of exercise. J Endocr Soc. 2020;4(2):bvaa007. https:\/\/doi.org\/10.1210\/jendso\/bvaa007.","journal-title":"J Endocr Soc"},{"issue":"41","key":"1364_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031102","volume":"101","author":"Y Lu","year":"2022","unstructured":"Lu Y, Xing C, Lv X, Zhang C, Liu G, Chen F, et al. Changes of ACE2 in different glucose metabolites and its relationship with COVID-19. Medicine (Baltimore). 2022;101(41):e31102. https:\/\/doi.org\/10.1097\/MD.0000000000031102.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"1364_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A phase 2 randomized trial of Survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2401755.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"1364_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.mce.2012.04.013","volume":"378","author":"E Matthew Morris","year":"2013","unstructured":"Matthew Morris E, Fletcher JA, Thyfault JP, Rector RS. The role of angiotensin II in nonalcoholic steatohepatitis. Mol Cell Endocrinol. 2013;378(1\u20132):29\u201340. https:\/\/doi.org\/10.1016\/j.mce.2012.04.013.","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"1364_CR19","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/hep4.1884","volume":"6","author":"IG Rajapaksha","year":"2022","unstructured":"Rajapaksha IG, Gunarathne LS, Asadi K, Laybutt R, Andrikopoulous S, Alexander IE, et al. Angiotensin converting enzyme-2 therapy improves liver fibrosis and glycemic control in diabetic mice with fatty liver. Hepatol Commun. 2022;6(5):1056\u201372. https:\/\/doi.org\/10.1002\/hep4.1884.","journal-title":"Hepatol Commun"},{"key":"1364_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179515","author":"V Nunes-Souza","year":"2024","unstructured":"Nunes-Souza V, Alenina N, Qadri F, Mosienko V, Santos RAS, Bader M, et al. ACE2 knockout mice are resistant to high-fat diet-induced obesity in an age-dependent manner. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25179515.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1364_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.gastro.2020.07.067","volume":"160","author":"JM Penninger","year":"2021","unstructured":"Penninger JM, Grant MB, Sung JJY. The role of angiotensin converting enzyme 2 in modulating gut microbiota, intestinal inflammation, and coronavirus infection. Gastroenterology. 2021;160(1):39\u201346. https:\/\/doi.org\/10.1053\/j.gastro.2020.07.067.","journal-title":"Gastroenterology"},{"key":"1364_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1404678","volume":"14","author":"L Song","year":"2024","unstructured":"Song L, Ji W, Cao X. Integrated analysis of gut microbiome and its metabolites in ACE2-knockout and ACE2-overexpressed mice. Front Cell Infect Microbiol. 2024;14:1404678. https:\/\/doi.org\/10.3389\/fcimb.2024.1404678.","journal-title":"Front Cell Infect Microbiol"},{"key":"1364_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1537456","volume":"15","author":"SW Smail","year":"2025","unstructured":"Smail SW, Albarzinji N, Salih RH, Taha KO, Hirmiz SM, Ismael HM, et al. Microbiome dysbiosis in SARS-CoV-2 infection: implication for pathophysiology and management strategies of COVID-19. Front Cell Infect Microbiol. 2025;15:1537456. https:\/\/doi.org\/10.3389\/fcimb.2025.1537456.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"1364_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-025-00733-7","volume":"11","author":"M Bredon","year":"2025","unstructured":"Bredon M, Hausfater P, Khalki L, Tijani Y, Cheikh A, Brot L, et al. Gut microbiota alterations are linked to COVID-19 severity in North African and European populations. NPJ Biofilms Microbiomes. 2025;11(1):106. https:\/\/doi.org\/10.1038\/s41522-025-00733-7.","journal-title":"NPJ Biofilms Microbiomes"},{"key":"1364_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1034818","volume":"13","author":"P Wang","year":"2022","unstructured":"Wang P, Guo R, Bai X, Cui W, Zhang Y, Li H, et al. Sacubitril\/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice. Front Endocrinol (Lausanne). 2022;13:1034818. https:\/\/doi.org\/10.3389\/fendo.2022.1034818.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1364_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1231621","volume":"14","author":"E Tian","year":"2023","unstructured":"Tian E, Wang F, Zhao L, Sun Y, Yang J. The pathogenic role of intestinal flora metabolites in diabetic nephropathy. Front Physiol. 2023;14:1231621. https:\/\/doi.org\/10.3389\/fphys.2023.1231621.","journal-title":"Front Physiol"},{"issue":"17","key":"1364_CR27","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1016\/j.cell.2025.05.010","volume":"188","author":"J Lin","year":"2025","unstructured":"Lin J, Nie Q, Cheng J, Zhong YN, Zhang T, Zhang X, et al. A microbial amino-acid-conjugated bile acid, tryptophan-cholic acid, improves glucose homeostasis via the orphan receptor MRGPRE. Cell. 2025;188(17):4530\u2013e4825. https:\/\/doi.org\/10.1016\/j.cell.2025.05.010.","journal-title":"Cell"},{"key":"1364_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2025.118696","volume":"302","author":"K Yan","year":"2025","unstructured":"Yan K, Wang S, Wang M, Yao Y, Liu X, Song J, et al. Modulating gut microbiota with SCFAs and high-fiber diets to mitigate PM(2.5)-induced hypertension in mice. Ecotoxicol Environ Saf. 2025;302:118696. https:\/\/doi.org\/10.1016\/j.ecoenv.2025.118696.","journal-title":"Ecotoxicol Environ Saf"},{"issue":"6","key":"1364_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf168","volume":"18","author":"XN Zhao","year":"2025","unstructured":"Zhao XN, Liu SX, Zhang S, Wang ZZ, Lin Z, Jian XL, et al. Association between serum short-chain fatty acid levels and the risk of all-cause and cardiovascular disease mortality in Chinese patients undergoing maintenance hemodialysis: a retrospective cohort study. Clin Kidney J. 2025;18(6):sfaf168. https:\/\/doi.org\/10.1093\/ckj\/sfaf168.","journal-title":"Clin Kidney J"},{"issue":"1","key":"1364_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-023-01803-5","volume":"22","author":"E Birkeland","year":"2023","unstructured":"Birkeland E, Gharagozlian S, Valeur J, Aas AM. Short-chain fatty acids as a link between diet and cardiometabolic risk: a narrative review. Lipids Health Dis. 2023;22(1):40. https:\/\/doi.org\/10.1186\/s12944-023-01803-5.","journal-title":"Lipids Health Dis"},{"issue":"11","key":"1364_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11906-022-01216-2","volume":"24","author":"C Xu","year":"2022","unstructured":"Xu C, Marques FZ. How dietary fibre, acting via the gut microbiome, lowers blood pressure. Curr Hypertens Rep. 2022;24(11):509\u201321. https:\/\/doi.org\/10.1007\/s11906-022-01216-2.","journal-title":"Curr Hypertens Rep"},{"key":"1364_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.964389","volume":"13","author":"J Shang","year":"2022","unstructured":"Shang J, Cui W, Guo R, Zhang Y, Wang P, Yu W, et al. The harmful intestinal microbial community accumulates during DKD exacerbation and microbiome-metabolome combined validation in a mouse model. Front Endocrinol (Lausanne). 2022;13:964389. https:\/\/doi.org\/10.3389\/fendo.2022.964389.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1364_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/cph4.70024","volume":"15","author":"N Kondapalli","year":"2025","unstructured":"Kondapalli N, Katari V, Dalal KK, Paruchuri S, Thodeti CK. Microbiota in Gut-Heart Axis: metabolites and mechanisms in cardiovascular disease. Compr Physiol. 2025;15(3):e70024. https:\/\/doi.org\/10.1002\/cph4.70024.","journal-title":"Compr Physiol"},{"issue":"1","key":"1364_CR34","doi-asserted-by":"publisher","first-page":"6372935","DOI":"10.1155\/2020\/6372935","volume":"2020","author":"V Dobrocsyova","year":"2020","unstructured":"Dobrocsyova V, Slamkova M, Krskova K, Balazova L, Suski M, Olszanecki R, et al. AVE0991, a nonpeptide angiotensin 1\u20137 receptor Agonist, improves glucose metabolism in the skeletal muscle of obese Zucker rats: possible involvement of Prooxidant\/Antioxidant mechanisms. Oxid Med Cell Longev. 2020;2020(1):6372935. https:\/\/doi.org\/10.1155\/2020\/6372935.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"1364_CR35","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-6016","volume":"11","author":"C Wu","year":"2023","unstructured":"Wu C, Chen Y, Zhou P, Hu Z. Recombinant human angiotensin-converting enzyme 2 plays a protective role in mice with sepsis-induced cardiac dysfunction through multiple signaling pathways dependent on converting angiotensin II to angiotensin 1\u20137. Ann Transl Med. 2023;11(1):13. https:\/\/doi.org\/10.21037\/atm-22-6016.","journal-title":"Ann Transl Med"},{"key":"1364_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2023.10.025","volume":"364","author":"P Lu","year":"2023","unstructured":"Lu P, Leslie F, Wang H, Sodhi A, Choi CY, Pekosz A, et al. Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation. J Control Release. 2023;364:1\u201311. https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.025.","journal-title":"J Control Release"},{"issue":"1","key":"1364_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01284-1","volume":"16","author":"XJ Zhang","year":"2024","unstructured":"Zhang XJ, Liu CC, Li ZL, Ding L, Zhou Y, Zhang DJ, et al. Sacubitril\/valsartan ameliorates tubulointerstitial fibrosis by restoring mitochondrial homeostasis in diabetic kidney disease. Diabetol Metab Syndr. 2024;16(1):40. https:\/\/doi.org\/10.1186\/s13098-024-01284-1.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"1364_CR38","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00567-2023","volume":"10","author":"M Bauer","year":"2024","unstructured":"Bauer M, Jorda A, Al-Jalali V, Wolfl-Duchek M, Bergmann F, Nussbaumer-Proll A, et al. Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled recombinant human ACE2. ERJ Open Res. 2024;10(1):00567\u20132023. https:\/\/doi.org\/10.1183\/23120541.00567-2023.","journal-title":"ERJ Open Res"},{"issue":"2","key":"1364_CR39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s41030-021-00164-7","volume":"7","author":"DA Hall","year":"2021","unstructured":"Hall DA, Hanrott K, Badorrek P, Berliner D, Budd DC, Eames R, et al. Effects of recombinant human angiotensin-converting enzyme 2 on response to acute hypoxia and exercise: a randomised, placebo-controlled study. Pulm Ther. 2021;7(2):487\u2013501. https:\/\/doi.org\/10.1007\/s41030-021-00164-7.","journal-title":"Pulm Ther"},{"issue":"17","key":"1364_CR40","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.15803","volume":"11","author":"YM Lestari","year":"2023","unstructured":"Lestari YM, Tarawan VM, Achadiyani A, Radhiyanti PT, Ray HRD, Lesmana R, et al. Exercise intensities modulate ACE2\/MasR\/eNOS pathway in male Wistar rat\u2019s lung. Physiol Rep. 2023;11(17):e15803. https:\/\/doi.org\/10.14814\/phy2.15803.","journal-title":"Physiol Rep"},{"key":"1364_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.120058","volume":"287","author":"R de Alcantara Santos","year":"2021","unstructured":"de Alcantara Santos R, Guzzoni V, Silva KAS, Aragao DS, de Paula Vieira R, Bertoncello N, et al. Resistance exercise shifts the balance of renin-angiotensin system toward ACE2\/Ang 1\u20137 axis and reduces inflammation in the kidney of diabetic rats. Life Sci. 2021;287:120058. https:\/\/doi.org\/10.1016\/j.lfs.2021.120058.","journal-title":"Life Sci"},{"issue":"7","key":"1364_CR42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/10641963.2020.1772812","volume":"42","author":"W Han","year":"2020","unstructured":"Han W, Wang M, Zhai X, Gan Q, Guan S, Qu X. Chemical renal denervation-induced upregulation of the ACE2\/Ang (1\u20137)\/Mas axis attenuates blood pressure elevation in spontaneously hypertensive rats. Clin Exp Hypertens. 2020;42(7):661\u20138. https:\/\/doi.org\/10.1080\/10641963.2020.1772812.","journal-title":"Clin Exp Hypertens"},{"issue":"4","key":"1364_CR43","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1165\/rcmb.2020-0322PS","volume":"64","author":"H Jia","year":"2021","unstructured":"Jia H, Neptune E, Cui H. Targeting ACE2 for COVID-19 therapy: opportunities and challenges. Am J Respir Cell Mol Biol. 2021;64(4):416\u201325. https:\/\/doi.org\/10.1165\/rcmb.2020-0322PS.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"1364_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00109-020-01880-4","volume":"98","author":"H Ma","year":"2020","unstructured":"Ma H, Wang YL, Hei NH, Li JL, Cao XR, Dong B, et al. AVE0991, a nonpeptide angiotensin-(1\u20137) mimic, inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E knockout mice. Journal of molecular medicine (Berlin, Germany). 2020;98(4):541\u201351. https:\/\/doi.org\/10.1007\/s00109-020-01880-4.","journal-title":"Journal of molecular medicine (Berlin, Germany)"},{"issue":"9","key":"1364_CR45","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/jdi.14044","volume":"14","author":"T Kato","year":"2023","unstructured":"Kato T, Murakami T, Yabe D, Harada N. Impact of the angiotensin receptor-neprilysin inhibitor in clinical diabetes management: potential benefits and pitfalls. J Diabetes Invest. 2023;14(9):1038\u201340. https:\/\/doi.org\/10.1111\/jdi.14044.","journal-title":"J Diabetes Invest"},{"key":"1364_CR46","doi-asserted-by":"publisher","first-page":"619524","DOI":"10.3389\/fphar.2021.619524","volume":"12","author":"G Kriszta","year":"2021","unstructured":"Kriszta G, Kriszta Z, Vancsa S, Hegyi PJ, Frim L, Eross B, et al. Effects of angiotensin-Converting enzyme inhibitors and angiotensin receptor blockers on angiotensin-Converting enzyme 2 levels: A comprehensive analysis based on animal studies. Front Pharmacol. 2021;12:619524. https:\/\/doi.org\/10.3389\/fphar.2021.619524.","journal-title":"Front Pharmacol"},{"issue":"24","key":"1364_CR47","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1001\/jama.2024.6774","volume":"331","author":"L Shen","year":"2024","unstructured":"Shen L, Lee MMY, Jhund PS, Granger CB, Anand IS, Maggioni AP, et al. Revisiting race and the benefit of RAS blockade in heart failure: a meta-analysis of randomized clinical trials. JAMA. 2024;331(24):2094\u2013104. https:\/\/doi.org\/10.1001\/jama.2024.6774.","journal-title":"JAMA"},{"issue":"15","key":"1364_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512111","volume":"24","author":"N Koumallos","year":"2023","unstructured":"Koumallos N, Sigala E, Milas T, Baikoussis NG, Aragiannis D, Sideris S, et al. Angiotensin regulation of vascular homeostasis: exploring the role of ROS and RAS blockers. Int J Mol Sci. 2023;24(15):12111. https:\/\/doi.org\/10.3390\/ijms241512111.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"1364_CR49","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1111\/bph.70063","volume":"182","author":"F Pu","year":"2025","unstructured":"Pu F, Liu Y, Ahmed FZ, Wang X, Green D, Zhang H. Advancing antihypertensive drug development. Br J Pharmacol. 2025;182(15):3389\u2013410. https:\/\/doi.org\/10.1111\/bph.70063.","journal-title":"Br J Pharmacol"},{"issue":"19","key":"1364_CR50","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1042\/CS20200570","volume":"134","author":"Q Li","year":"2020","unstructured":"Li Q, Grant MB, Richards EM, Raizada MK. ACE2 as therapeutic agent. Clin Sci Lond. 2020;134(19):2581\u201395. https:\/\/doi.org\/10.1042\/CS20200570.","journal-title":"Clin Sci Lond"},{"issue":"5","key":"1364_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15644","volume":"9","author":"AD Kunvariya","year":"2023","unstructured":"Kunvariya AD, Dave SA, Modi ZJ, Patel PK, Sagar SR. Exploration of multifaceted molecular mechanism of angiotensin-converting enzyme 2 (ACE2) in pathogenesis of various diseases. Heliyon. 2023;9(5):e15644. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15644.","journal-title":"Heliyon"},{"issue":"6","key":"1364_CR52","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.1007\/s00210-025-03819-3","volume":"398","author":"B Thakkar","year":"2025","unstructured":"Thakkar B, Dadhaniya H, Dudhat K. Exploring hypertension-linked diseases: a comprehensive review of innovative drug combinations with enhanced therapeutic potential. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(6):6643\u201373. https:\/\/doi.org\/10.1007\/s00210-025-03819-3.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"1364_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12024","volume":"12","author":"MA Simon","year":"2022","unstructured":"Simon MA, Hanrott K, Budd DC, Torres F, Grunig E, Escribano-Subias P, et al. An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension. Pulm Circ. 2022;12(1):e12024. https:\/\/doi.org\/10.1002\/pul2.12024.","journal-title":"Pulm Circ"},{"issue":"7","key":"1364_CR54","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.006939","volume":"13","author":"K Wang","year":"2020","unstructured":"Wang K, Basu R, Poglitsch M, Bakal JA, Oudit GY. Elevated angiotensin 1\u20137\/angiotensin II ratio predicts favorable outcomes in patients with heart failure. Circ Heart Fail. 2020;13(7):e006939. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.006939.","journal-title":"Circ Heart Fail"},{"key":"1364_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ahj.2020.01.007","volume":"222","author":"JC Tardif","year":"2020","unstructured":"Tardif JC, Dube MP, Pfeffer MA, Waters DD, Koenig W, Maggioni AP, et al. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. Am Heart J. 2020;222:157\u201365. https:\/\/doi.org\/10.1016\/j.ahj.2020.01.007.","journal-title":"Am Heart J"},{"issue":"1","key":"1364_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02942-2","volume":"24","author":"P Sward","year":"2020","unstructured":"Sward P, Edsfeldt A, Reepalu A, Jehpsson L, Rosengren BE, Karlsson MK. Age and sex differences in soluble ACE2 may give insights for COVID-19. Crit Care. 2020;24(1):221. https:\/\/doi.org\/10.1186\/s13054-020-02942-2.","journal-title":"Crit Care"},{"key":"1364_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/genes11070741","author":"C Strafella","year":"2020","unstructured":"Strafella C, Caputo V, Termine A, Barati S, Gambardella S, Borgiani P, et al. Analysis of ACE2 genetic variability among populations highlights a possible link with COVID-19-related neurological complications. Genes. 2020. https:\/\/doi.org\/10.3390\/genes11070741.","journal-title":"Genes"},{"issue":"39","key":"1364_CR58","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1093\/eurheartj\/ehac374","volume":"43","author":"JC Tardif","year":"2022","unstructured":"Tardif JC, Pfeffer MA, Kouz S, Koenig W, Maggioni AP, McMurray JJV, et al. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. Eur Heart J. 2022;43(39):3947\u201356. https:\/\/doi.org\/10.1093\/eurheartj\/ehac374.","journal-title":"Eur Heart J"},{"issue":"14","key":"1364_CR59","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jacc.2020.02.031","volume":"75","author":"B Zhang","year":"2020","unstructured":"Zhang B, Xu H, Zhang H, Liu Q, Ye Y, Hao J, et al. Prognostic value of N-terminal pro-B-type natriuretic peptide in elderly patients with valvular heart disease. J Am Coll Cardiol. 2020;75(14):1659\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.031.","journal-title":"J Am Coll Cardiol"},{"key":"1364_CR60","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.2147\/IJGM.S539237","volume":"18","author":"P Xu","year":"2025","unstructured":"Xu P. Gut microbiota metabolites targeting the immune response in sepsis: mechanisms and therapies. Int J Gen Med. 2025;18:4709\u201334. https:\/\/doi.org\/10.2147\/IJGM.S539237.","journal-title":"Int J Gen Med"},{"issue":"1","key":"1364_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1823-x","volume":"21","author":"A Khan","year":"2017","unstructured":"Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234. https:\/\/doi.org\/10.1186\/s13054-017-1823-x.","journal-title":"Crit Care"},{"key":"1364_CR62","doi-asserted-by":"publisher","first-page":"102383","DOI":"10.1016\/j.eclinm.2023.102383","volume":"68","author":"SM Lobo","year":"2024","unstructured":"Lobo SM, Plantefeve G, Nair G, Joaquim Cavalcante A, Franzin de Moraes N, Nunes E, et al. Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2\/3 trial. EClinicalMedicine. 2024;68:102383. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102383.","journal-title":"EClinicalMedicine"},{"key":"1364_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021703","author":"R Nevola","year":"2023","unstructured":"Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R, et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24021703.","journal-title":"Int J Mol Sci"},{"key":"1364_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102976","volume":"60","author":"ME Ortiz","year":"2020","unstructured":"Ortiz ME, Thurman A, Pezzulo AA, Leidinger MR, Klesney-Tait JA, Karp PH, et al. Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract. EBioMedicine. 2020;60:102976. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102976.","journal-title":"EBioMedicine"},{"issue":"1","key":"1364_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2653-0","volume":"19","author":"R Llewellyn-Bennett","year":"2018","unstructured":"Llewellyn-Bennett R, Edwards D, Roberts N, Hainsworth AH, Bulbulia R, Bowman L. Post-trial follow-up methodology in large randomised controlled trials: a systematic review. Trials. 2018;19(1):298. https:\/\/doi.org\/10.1186\/s13063-018-2653-0.","journal-title":"Trials"},{"key":"1364_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.628885","volume":"8","author":"M Ma","year":"2021","unstructured":"Ma M, Xu Y, Su Y, Ong SB, Hu X, Chai M, et al. Single-cell transcriptome analysis decipher new potential regulation mechanism of ACE2 and NPs signaling among heart failure patients infected with SARS-CoV-2. Front Cardiovasc Med. 2021;8:628885. https:\/\/doi.org\/10.3389\/fcvm.2021.628885.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"1364_CR67","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10286-020-00720-2","volume":"30","author":"D Medina","year":"2020","unstructured":"Medina D, Mehay D, Arnold AC. Sex differences in cardiovascular actions of the renin-angiotensin system. Clin Auton Res. 2020;30(5):393\u2013408. https:\/\/doi.org\/10.1007\/s10286-020-00720-2.","journal-title":"Clin Auton Res"},{"key":"1364_CR68","doi-asserted-by":"publisher","unstructured":"Martins FL, Tavares CAM, Malagrino PA, Rentz T, Benetti A, Rios TMS, et al. Sex differences in the lung ACE\/ACE2 balance in hypertensive rats. Biosci Rep. 2021;41(12). https:\/\/doi.org\/10.1042\/BSR20211201.","DOI":"10.1042\/BSR20211201"},{"issue":"2","key":"1364_CR69","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s11357-020-00314-w","volume":"43","author":"M AlGhatrif","year":"2021","unstructured":"AlGhatrif M, Tanaka T, Moore AZ, Bandinelli S, Lakatta EG, Ferrucci L. Age-associated difference in circulating ACE2, the gateway for SARS-COV-2, in humans: results from the InCHIANTI study. Geroscience. 2021;43(2):619\u201327. https:\/\/doi.org\/10.1007\/s11357-020-00314-w.","journal-title":"Geroscience"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-026-01364-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-026-01364-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-026-01364-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:18:05Z","timestamp":1773659885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-026-01364-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1364"],"URL":"https:\/\/doi.org\/10.1007\/s11906-026-01364-9","relation":{},"ISSN":["1534-3111"],"issn-type":[{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}